Safety and pharmacokinetics of tabalumab in patients with rheumatoid arthritis or systemic lupus erythematosus

Trial Profile

Safety and pharmacokinetics of tabalumab in patients with rheumatoid arthritis or systemic lupus erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Dec 2015 Status changed from not stated to completed.
    • 17 Dec 2015 New trial record
    • 09 Dec 2015 Results published in the British Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top